Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue ...

Gilead’s Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs. By Matthew Herper Jan. 22, 2024. Reprints. Yichuan Cao/Sipa USA via AP Images.

Gilead Sciences said on Monday a late-stage trial of its antibody-drug conjugate Trodelvy failed to show that it significantly improved survival for previously treated patients with advanced non ...

Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but ...

Many Gilead Sciences investors have lost faith in Trodelvy in HR-positive, HER2-negative breast cancer after disappointing data on tumor progression. But the antibody-drug conjugate has now made a ...

Sept 7 (Reuters) - Gilead Sciences Inc's , opens new tab Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ...

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...

The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market for the TROP2-targeting ...

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer. Sep. 05, 2024 8:00 AM ET Gilead Sciences, Inc. (GILD) ...

Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1. Sponsored Bank Accounts ...